License and Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2015

Baxalta [Member]

Schedule of Revenue Recognized and Assets and Liabilities under Collaborative Arrangements

During the years ended December 31, 2015 and 2014, the Company recognized revenue based on the following components of the Baxalta Agreement:

	Year Ended December 31,		Year Ended December 31,
(in thousands)	2015		2014
Proportional performance revenue recognition model	$	64,930	$	10,460
Substantive milestones		20,000		—
Total	$	84,930	$	10,460

As of December 31, 2015 and 2014, the Company maintained the following assets and liabilities related to the Baxalta Agreement:

(in thousands)	December 31, 2015		December 31, 2014
Accounts receivable, billed	$	1,336	$	—
Accounts receivable, unbilled		626		1,615
Deferred revenue		97,365		91,156

Sanofi [Member]

Schedule of Revenue Recognized and Assets and Liabilities under Collaborative Arrangements

During the years ended December 31, 2014 and 2013, the Company recognized revenue based on the following components of the Sanofi agreement:

	Years ended December 31,
(in thousands)	2014		2013
Upfront payment	$	39,306	$	5,000
Milestone payment		16,377		2,083
Development services		18,904		36,283
Manufacturing services and other		17,709		3,867
Total	$	92,296	$	47,233

As of December 31, 2015, the Company maintained no assets or liabilities related to the Sanofi Agreement. As of December 31, 2014, the Company maintained the following assets and liabilities related to the Sanofi agreement:

(in thousands)	December 31, 2014
Accounts receivable, billed	$	369
Accounts receivable, unbilled		1,282
Deferred revenues		—